Share this with FacebookShare this with TwitterShare this with LinkedInEmail this pagePrint this page
FOX4: Saint Luke’s Launches Global Clinical Trial to Investigate Potential COVID-19 Treatment
Saint Luke’s Mid America Heart Institute launches a global clinical trial to investigate whether the diabetes drug dapagliflozin could be a treatment for patients with COVID-19.
Dr. Mikhail Kosiborod, Saint Luke's cardiologist, is serving as the principal investigator for the study which will enroll 900 patients globally.